Personalis (NASDAQ:PSNL) Price Target Increased to $7.25 by Analysts at Needham & Company LLC

Personalis (NASDAQ:PSNL) had its price target hoisted by investment analysts at Needham & Company LLC from $5.50 to $7.25 in a report released on Friday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Needham & Company LLC’s price target points to a potential upside of 21.04% from the stock’s previous close.

Separately, Lake Street Capital assumed coverage on shares of Personalis in a report on Tuesday, April 30th. They issued a “buy” rating and a $4.00 target price on the stock.

Personalis Price Performance

Shares of PSNL opened at $5.99 on Friday. Personalis has a 1-year low of $0.89 and a 1-year high of $7.20. The stock has a market cap of $311.11 million, a price-to-earnings ratio of -3.15 and a beta of 1.85. The firm has a 50 day simple moving average of $2.35 and a 200-day simple moving average of $1.75.

Personalis (NASDAQ:PSNL) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.34) by $0.10. Personalis had a negative return on equity of 56.87% and a negative net margin of 101.78%. The company had revenue of $22.58 million during the quarter, compared to the consensus estimate of $19.81 million. During the same quarter last year, the business posted ($0.50) earnings per share. On average, equities analysts expect that Personalis will post -1.17 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Personalis

A number of hedge funds and other institutional investors have recently made changes to their positions in PSNL. Public Employees Retirement System of Ohio purchased a new position in Personalis during the first quarter worth about $29,000. Virtu Financial LLC acquired a new position in shares of Personalis during the 1st quarter valued at about $41,000. Price T Rowe Associates Inc. MD lifted its holdings in shares of Personalis by 58.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 95,000 shares of the company’s stock worth $142,000 after acquiring an additional 34,900 shares during the period. Quadrature Capital Ltd acquired a new stake in shares of Personalis in the fourth quarter worth approximately $152,000. Finally, Howland Capital Management LLC grew its holdings in Personalis by 392.8% in the first quarter. Howland Capital Management LLC now owns 211,118 shares of the company’s stock valued at $315,000 after purchasing an additional 168,274 shares during the period. Hedge funds and other institutional investors own 61.91% of the company’s stock.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.